Article

Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 Study

2024-06-28

Abstract excerpt

<title>Abstract</title> <p>REZOR is a multicenter, double-blinded, randomized phase 3 study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). The study included eligible patients from 50 hospitals across China. Those who had been histologically or cytologically c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 684b4d1c-f774-55f5-b0e1-3988c228fdae
DOI: 10.21203/rs.3.rs-4616293/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Rezivertinib versus Gefitinib as First-line Therapy for EGFR-mutated Locally Advanced or Metastatic NSCLC Patients (REZOR): A Multicenter, Double-blinded, Randomized Phase 3 StudyDOI 10.21203/rs.3.rs-4616293/v1Read

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.Semantic proximity Read

REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.Semantic proximity Read

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.Semantic proximity Read

Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profileSemantic proximity Read

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.Semantic proximity Read

Efficacy of First-Third generation EGFR inhibitor combined with chemotherapy as first-line treatment for advanced lung adenocarcinoma in a real-world settingSemantic proximity Read

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.Semantic proximity Read

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.Semantic proximity Read

[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].Semantic proximity Read

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.Semantic proximity Read